AIM: It is controversial whether patients with non-ulcer dyspepsia (NUD) respond differently to Helicobacter pylori (H pylori) eradication treatment than those with peptic ulcer disease (PUD). To review the evidence f...AIM: It is controversial whether patients with non-ulcer dyspepsia (NUD) respond differently to Helicobacter pylori (H pylori) eradication treatment than those with peptic ulcer disease (PUD). To review the evidence for any difference in H pylorieradication rates between PUD and NUD patients. METHODS: A literature search for full articles and meeting abstracts to July 2004 was conducted. We included studies evaluating the efficacy of a proton pump inhibitor (P) or ranitidine bismuth citrate (RBC) plus two antibiotics of clarithromycin (C), amoxicillin (A), metronidazole (M), or P-based quadruple therapies for eradicating the infection. RESULTS: Twenty-two studies met the criteria. No significant difference in eradication rates was found between PUD and NUD patients when treated with 7-d RBCCA, 10-d PCA or P-based quadruple therapies. When the 7-d PCA was used, the pooled H pylori eradication rate was 82.1% (431/525) and 72.6% (448/617) for PUD and NUD patients, respectively, yielding a RR of 1.15 (95%CI 1.01-1.29). However, the statistically significant difference was seen only in meeting abstracts, but not in full publications. CONCLUSION: There is no convincing evidence to suggest that NUD patients respond to H pylori eradication treatments differently from those with PUD, although a trend exists with the 7-d PCA therapy.展开更多
AIM： To compare the effects of treatment of H pyloriinfected individuals with the effects of treatment of individuals as well as all Hpylori-infected family members.METHODS： H pylori-positive patients with similar d...AIM： To compare the effects of treatment of H pyloriinfected individuals with the effects of treatment of individuals as well as all Hpylori-infected family members.METHODS： H pylori-positive patients with similar demographic specifications were prospectively randomized with respect to treatment, with a triple regimen of either patients and all Hpylori-positive family members living together （group Ⅰ ） or patients only （group Ⅱ）. Nine months after treatment, all patients were assessed for H pylori positivity.RESULTS： There were 70 H pylori-positive patients in each group; patients in groups Ⅰ and Ⅱ lived with 175 and 190 Hpylori-positive relatives, respectively. Age, sex and Hpylori positivity rate were similar in both groups of relatives. Nine months after 14 d standard triple therapy, Hpylori positivity was 7.1% in group I patients and 38.6% in group 11 patients [P 〈 0.01, OR = 8.61 95% confidence interval （CI）： 2.91-22.84].CONCLUSION： The present results indicate bad environmental hygienic conditions and close intra-familial relationships are important in H pylori contamination. These findings indicate all family members of H pyloripositive individuals should be assessed for H pylori positivity, particularly in developing countries where H pylori prevalence is high; they also suggest patients, their spouses and all H pyloN-positive family members of H pylori-positive individuals should be treated for H pylori infection.展开更多
文摘AIM: It is controversial whether patients with non-ulcer dyspepsia (NUD) respond differently to Helicobacter pylori (H pylori) eradication treatment than those with peptic ulcer disease (PUD). To review the evidence for any difference in H pylorieradication rates between PUD and NUD patients. METHODS: A literature search for full articles and meeting abstracts to July 2004 was conducted. We included studies evaluating the efficacy of a proton pump inhibitor (P) or ranitidine bismuth citrate (RBC) plus two antibiotics of clarithromycin (C), amoxicillin (A), metronidazole (M), or P-based quadruple therapies for eradicating the infection. RESULTS: Twenty-two studies met the criteria. No significant difference in eradication rates was found between PUD and NUD patients when treated with 7-d RBCCA, 10-d PCA or P-based quadruple therapies. When the 7-d PCA was used, the pooled H pylori eradication rate was 82.1% (431/525) and 72.6% (448/617) for PUD and NUD patients, respectively, yielding a RR of 1.15 (95%CI 1.01-1.29). However, the statistically significant difference was seen only in meeting abstracts, but not in full publications. CONCLUSION: There is no convincing evidence to suggest that NUD patients respond to H pylori eradication treatments differently from those with PUD, although a trend exists with the 7-d PCA therapy.
文摘AIM： To compare the effects of treatment of H pyloriinfected individuals with the effects of treatment of individuals as well as all Hpylori-infected family members.METHODS： H pylori-positive patients with similar demographic specifications were prospectively randomized with respect to treatment, with a triple regimen of either patients and all Hpylori-positive family members living together （group Ⅰ ） or patients only （group Ⅱ）. Nine months after treatment, all patients were assessed for H pylori positivity.RESULTS： There were 70 H pylori-positive patients in each group; patients in groups Ⅰ and Ⅱ lived with 175 and 190 Hpylori-positive relatives, respectively. Age, sex and Hpylori positivity rate were similar in both groups of relatives. Nine months after 14 d standard triple therapy, Hpylori positivity was 7.1% in group I patients and 38.6% in group 11 patients [P 〈 0.01, OR = 8.61 95% confidence interval （CI）： 2.91-22.84].CONCLUSION： The present results indicate bad environmental hygienic conditions and close intra-familial relationships are important in H pylori contamination. These findings indicate all family members of H pyloripositive individuals should be assessed for H pylori positivity, particularly in developing countries where H pylori prevalence is high; they also suggest patients, their spouses and all H pyloN-positive family members of H pylori-positive individuals should be treated for H pylori infection.
